Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilorasertib

Drug Profile

Ilorasertib

Alternative Names: A-968660.0; Abbott-968660; ABT-348

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; National Cancer Institute (USA); University of Chicago
  • Class 2 ring heterocyclic compounds; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Platelet-derived growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 05 Jun 2017 Pooled pharmacokinetics/pharmacodynamics analysis of two phase I trials in Solid tumours (Late-stage disease, Metastatic disease) presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Aug 2016 Phase-II clinical trials in Solid tumours (Late-stage disease, Monotherapy) in USA (PO) (NCT02478320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top